PFE trade ideas
$PFE - At channel bottom again! Selling has been vicious for PFE. Fallen back to the channel base line again after failing to break above $42.00. At $ 38.00 ish price with 4% plus dividend and 4 high quality acquisitions selling seems unjustified. The ER on 05/02/2023 will be the turn that bulls has been looking for. I still stand by the bottom call. Targets - $40.00, $42.00, $44. Gap $47.50.
PFE Large Cap Pharma increased its dividendPFE just raised its dividend On the chart it has been trending downward
as shown also by a down sloping anchored VWAP bands. Price is currently
sitting at long term support and two standard deviations below VWAP.
It appears to be ready to reverse from the deep undervalued area.
In confirmation, teh voume indicator shows moderate increased relative
volume compared with March. I see this as a good opportunity to enter
a swing long trade or investment. PFE has its increased dividend as a
hint to shareholders of increasing earnings also with the next generation of
COVID vaccines in the pipeline along with a diversified line of other
products. The only thing that will slow PFE down in federal legislation to
limit the retail MSRP prices of its products to all consumers including those
with no insurance and commercial coverage outside federal programs.
PFE is solid as a rock. I see the buy signal.
$PFE - Today price action makes things difficultNYSE:PFE #PFE broke down pretty bad hitting the bottom of the modest up trend channel. The health care sector indexes like NASDAQ:IBB , AMEX:XBI and AMEX:XLV saw red.
The selling pressure for PFE was worse than its peers with no recovery towards the end of the day.
PFE needs a bounce above $40.87 to recover the damage.
$PFE: Trend signal predicts a bottom$PFE has a similar setup to $MRNA here, both are attractive buys from a valuation and technical standpoint here and have been beaten down lately due to the situation with rates, banking woes and negative news about COVID vaccines, COVID lock downs, etc. (a general more negative perception of health measures taken by the US govt since 2020 likely part of the reason for the decline here)
The companies still have valuable IP and profitable businesses that can rerate higher over time, specially now that the broad market appears to be trending up long term again.
Best of luck!
Cheers,
Ivan Labrie.
PFE 1H T2 level Upthrust in 1/2 correction and resistance levelDaily chart formation
Trend trade 3IBK
+ short balance
+ resistance level
- expanding CREEK
+ volumed 2 Ut
- month support level
Hourly chart:
Conservative trend trade 3IBK
+ short impulse
+ 1/2 correction
+ resistance zone
+ T2 level
+ volumed 2Ut
💉 Pfizer, Inc. Goes Bearish | 44, 39 and 34 Coming NextThe PFE stock, Pfizer, Inc., looks like is about to take a deep dive... Going red... Let's have a look!
The most obvious signal is the weekly candle today moving below EMA50, telling us that this stock is preparing to drop for months.
Pfizer, Inc. peaked December 2021.
In mid-December 2022 PFE printed the inverted hammer bearish candlestick pattern or shooting star.
This candlestick came at a long-term lower high (Dec. 2022 vs Dec. 2021).
Trading volume has been decreasing since November 2020.
The RSI has moved below 50, now bearish, and is trending down strong.
The next and at the same time critical support level is 48.24.
If this level breaks, PFE is going to move to 39.91 as a new low with even lower possible, but this level is the main one.
Bearish target of 39.91 at 0.618 Fib. retracement level followed by 0.786 or 33.98.
There is something going on at Twitter as well... I don't know...
Do your own research... Not only about trading but also about your health.
Thank you for reading.
Namaste.
PFE New Position {Calls}New Position NEW POSITION+ BOUGHT 5 PFE Jun1623 40 CALL @ 2.89 15:14:38 OptTrader
Very nice channel good risk reward
Pfizer Stock: More Than Just COVID-19 VaccinesYou may be familiar with the negative sentiment surrounding Pfizer, with many citing the company's heavy reliance on its COVID-19 vaccine Comirnaty and antiviral therapy Paxlovid as a cause for concern. In addition to this, several of Pfizer's top-selling drugs will face patent expirations in the near future, leading many to believe that the company's stock will suffer.
While there are certainly challenges facing Pfizer, the conclusion that its stock will suffer is flawed. Despite the company's current predicament, there is a lot to be excited about. Let's explore why Pfizer's stock is becoming increasingly attractive.
Over the past five weeks, Pfizer has received a string of positive news. The U.S. Food and Drug Administration (FDA) approved Cibinqo for the treatment of adolescents with atopic dermatitis, marking a significant milestone for the company's growth strategy. Additionally, a late-stage study evaluating the combination of Talzenna and Xtandi to treat metastatic castration-resistant prostate cancer produced positive results, reducing the risk of disease progression or death by 37%.
Furthermore, Pfizer announced that regulatory applications for elranatamab had been accepted by the FDA and the European Medicines Agency for the treatment of multiple myeloma. The company expects FDA approval to be granted later this year. In addition, an FDA advisory committee voted to approve Pfizer's respiratory syncytial virus (RSV) vaccine for older adults, which could open up a major market opportunity for the company.
On March 10, the FDA approved Zavzpret for the treatment of migraine. Pfizer acquired the drug as part of its purchase of Biohaven in 2022. The company also announced plans to acquire Seagen for $43 billion, which caused Pfizer's stock to rise significantly. The acquisition will provide Pfizer with four approved cancer drugs and promising antibody-drug conjugates (ADCs) that could generate $10 billion in risk-adjusted revenue by 2030.
Despite all of these positive developments, Pfizer's stock remains undervalued by investors. Its price is still nearly 35% below its late 2021 high, trading at just 12 times expected earnings. However, the company's dividend has risen to 4.1%, its highest level since mid-2021.
Investors seem to be fixated on the difficulties associated with COVID-19 and its treatment, but Pfizer predicts that even on this front, there is good news to come. The company expects demand for Comirnaty to rise to 98 million doses by 2026 due to the launch of the combination flu vaccine COVID. Additionally, demand for Paxlovid is predicted to grow steadily over the next few years, with the possibility of promoting antiviral therapy in China.
In conclusion, while there are certainly challenges facing Pfizer, the outlook for the company's stock is better than many people think. Despite the conventional wisdom that Pfizer's stock will suffer, the company is making significant strides towards achieving its goals. Investors should take note of the recent positive developments and consider investing in this pharmaceutical giant.
PFE set for a reboundPFE beat analysts' estimates on EPS but provided an outlook that didn`t meet expectations. However, The Co expects revenues to grow by 7-9% in 2023. Considering its plans to boost business by acquiring SGEN, the current market cap looks attractive as a reverse to mean play and a fundamentally driven long-term investment case.
Pattern?Seems like another one that could be following this pattern. If it does, it's looking at a move to about $46-$47 before meeting that top envelope.
3/17 Watchlist + NotesGoing off of yesterday's watchlist and notes, we were expecting bullish movement on SPY and we got it. Very strong close again on SPY leads me to believe we will see a push higher again tomorrow, but I am not entirely sure how much higher. With that being said, I think we are set for a solid friday session. The scanner only had 5 tickers on it today with our main focus being on PFE but I will get into that later. tickers and bias include:
KO - 3-1 : Slightly Bullish
JNJ - 2-1: Slightly Bullish
BABA - 2-1 : Slightly Bearish
HD - 2-1-1: Neutral
CAT - 2-1: Neutral
PFE - 3-1: Bullish
PFE is my main focus for tomorrow. It has a similar setup to DOCU from yesterday's list, which is an inside day with a gap to the upside, while having an underlying bullish bias.
Looking to break 40.49. If this happens, we target 40.82, 41.13, and 41.26 (Top of daily fair value gap, high of day from the day that created the most recent FVG, and high of last week/bottom of second most recent daily FVG).
Overall just going to play it like any other day and watch what SPY and VIX are doing while seeing if any of the inside days from this list breakout. If They break in the direction that SPY is moving then I will consider playing them. I do want to mention that besides PFE, JNJ, and HD, the other setups are not ideal to play, but I want to include them anyways because 1, they were on the scanner, and 2, sometimes these setups surprise me with how well they perform regardless of how they look at first.
short position on PFEMy strategy is based on price action with the reading of certain indicators that I like while respecting all the values that define the stock maket
PFEI really like this setup here , not just because of PFE chart but because XLV sector itself is way overbought amd I think the position PFE is in on its chart makes it a prime beneficiary of any rebound in the sector.
Easy entry and stop loss here...
Entry Over - 40.00
Stop loss 38.50
1st target is 44$ or .5 fib
I won't stick around for the entire reversal but I will play till 44
$PFE longWay oversold. RSI is super low.
Long-term leap is good too, but at this time I go with shares.
Bought @ $40.49
[PFE] - Neutral | Pivotal Point. Currently in a deep discount from the 10-Oct to 12-Dec'22 swing high. Almost fully retraced.
So we see PD arrays and potential draws on liquidity in each direction.
I am marginally more bullish than bearish based off the relatively equal highs (REHs) left at the 12-Dec high. Too clean. BUT, likely looking to purge some sellside liquidity prior to the move back higher.
$PFE - I am calling bottom#PFE Pfizer will bottom between $39.39 - $38. Yep. I committed a sin of calling bottoms. (May stock God forgive me.)🙏
Pfizer PFE Long Weekly and MonthlyBuy Feb-24-23 43.5 Calls @ 0.1 Limit to Open (Weekly)
Buy Mar-24-23 47 Calls @ 0.11 Limit to Open (Monthly (W))
$PFE - Over done? #PFESo #pfizer has been under relentless selling pressure. Is it over done? Let's look at a few things.
1. Every down turn saw an average of -24.46% peak to trough.
2. Stock V- bottomed after that.
3. Currently stock down -27.27% from its recent peak.
4. price at 100% fib extension
5. RSI same as covid low!
Looks a little overdone to me. What do you think?
PFE ready to fallAfter 9 consecutive weeks of higher lows, NYSE:PFE has broken down.
The chart has been streaky all year: Slow but steady marches downward from January to March, then July to October.
Honestly just looks like it's overdue for a fall, maybe hitting 38 by mid-March 2023.
PFE Screams `fff FED BUY ME NOW`A strong support and a nice bullish divergence.
Great fundamentals and great value.
If it is not gonna bounce from here lower fib support 37.21 USD is my all in price to enter.
First target in 3 to 4 months is 54.35 USD
I would stop below 37
Possible Head & Shoulders patternThe head and shoulders pattern forms when a stock's price rises to a peak and then declines back to the base of the prior up-move. Then, the price rises above the previous peak to form the "head" and then declines back to the original base. Finally, the stock price peaks again at about the level of the first peak of the formation before falling back down.
